Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.35 |
| ▸ | WDR5 | P61964 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3686716 | 0.85 | RAB9A (0.48) | RAB9ANPC1HSP90AA1SLC5A7MAPK1 | |
| SCHEMBL3511082 | 0.82 | RAB9A (0.43) | RAB9ANPC1HSP90AA1SLC5A7MAPK1 | |
| SCHEMBL3513838 | 0.80 | MAPK1 (0.41) | RAB9ANPC1HSP90AA1SLC5A7MAPK1 | |
| SCHEMBL3508887 | 0.80 | MAPK1 (0.41) | RAB9ANPC1HSP90AA1SLC5A7MAPK1 | |
| SCHEMBL3509902 | 0.80 | TSHR (0.46) | RAB9ANPC1HSP90AA1SLC5A7NAMPT | |
| SCHEMBL3647405 | 0.78 | ENPP2 (0.52) | RAB9ANPC1HSP90AA1SLC5A7NAMPT | |
| SCHEMBL3511239 | 0.76 | SLC5A7 (0.46) | RAB9ANPC1HSP90AA1SLC5A7NAMPT | |
| SCHEMBL3509630 | 0.76 | ADORA2A (0.46) | RAB9ANPC1HSP90AA1SLC5A7MAPK1 | |
| SCHEMBL3509460 | 0.76 | SLC5A7 (0.45) | RAB9ANPC1HSP90AA1SLC5A7NAMPT | |
| SCHEMBL3687556 | 0.73 | RAB9A (0.50) | RAB9ANPC1SLC5A7PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178837-A2 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-04-28 | — | — | EP | claimed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | RAB9A 3199/4885NPC1 204/4885HSP90AA1 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.